Skip to content

MHC-II-restricted neoantigen expression drives tumor infiltration, activation, and maintenance of nonspecific T cells in lung cancer 2251169

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

An unappreciated role for neoantigen-specific CD4+ T cells in promoting tumorigenesis and actively coordinating non-specific Passenger T cell responses within tumors is revealed.

Abstract

Cancer mutations can result in the expression of tumor-specific “neoantigens” that are targeted by T cells. Neoantigen expression drives robust T cell infiltration of tumors across cancer models, yet most of these T cells are not specific for the neoantigens and contain both pathogenic and immunosuppressive subsets. We sought to investigate how neoantigen-specific CD4+ T cells orchestrate nonspecific “Passenger” T cell responses within tumors and determine their impact on tumor progression. Our studies used an autochthonous murine model of lung adenocarcinoma (KrasG12D/+; tp53-/-) in which tumors are synchronously initiated via lentiviral delivery of Cre recombinase with neoantigen, and employed flow cytometry, histological analyses, single-cell transcriptomics, and temporal immune cell perturbations. Expression of a single MHC-II-restricted neoantigen (mITGB1) unexpectedly promoted tumor development. mITGB1 expression drove robust intratumoral enrichment of CD4+ and CD8+ Passenger T cells compared to mITGB1-neg controls. A fraction of Passenger T cells in mITGB1+ tumors uniquely displayed hallmarks of antigen experience, clonal expansion, and readily formed aggregates with B cells. Passenger T cells persisted in mITGB1+ tumors for at least three weeks, while lymphocytes in mITGB1-neg tumors rapidly vanished if cells could not traffic from the periphery. Critically, long-term maintenance of Passenger T cells within tumors required continuous expression of the neoantigen. Our study reveals an unappreciated role for neoantigen-specific CD4+ T cells in promoting tumorigenesis and actively coordinating non-specific Passenger T cell responses within tumors. Paradoxically, neoantigen expression may furnish the tumor microenvironment with novel T cell specificities and unlock cell states that support tumor growth alongside populations that work to combat progression. Jane Coffin Childs Fund, Hope Funds for Cancer Research Lymphocyte Differentiation and Peripheral Maintenance (LYM)

View source

Similar papers

Sep 2026

Abstract B084: Tracking tumor-specific CD4 T cells in pancreatic cancer reveals an essential role for cognate interactions with myeloid cells in remodeling the tumor microenvironment following immunotherapy

Our study identified an antigen (Ag)-specific CD4 T cell population in a preclinical orthotopic model of pancreatic ductal adenocarcinoma (PDA) that, upon expansion, elicited robust antitumor control. We developed an affinity-enhanced MHC-II tetramer to follow the endogenous tumor-specific CD4 T cells during pancreat...

Eduardo Cruz-Hinojoza, Zoe C. Schmichen, Sindri M. Bonner et al. · 0 citations
Open access Sep 2026

IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. Although major histocompatibility complex class II (MHC-II) is typically expressed by professional antigen-presenting cells, its regulation and significance in malignant PDAC cells remain un...

Can-Ping Chen, Yi Zhang, Xi Li et al. · 0 citations
Sep 2026

KRAS-G12C inhibition-induced enrichment of MHC-Ihigh immune-active tumor cells directs immune-effector TME development to augment therapeutic efficacy.

Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G12Ci impacts the tumor immune microenvironment and its association with resistance. We investigated the immune modulatory impact o...

Mohammed L. Ibrahim, Dana Foresman, Hong Zheng et al. · 0 citations
Open access Sep 2026

IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8+ T cells while restraining regulatory T-cell accumulation

Abstract Background Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8+ T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and a...

Kathryn M. Laporte, Janika Põder, D. Ivanova et al. · 0 citations
Open access Aug 2026

Molecular heterogeneity and clonal origin of CCR8+ effector regulatory T cells in human cancer

CD4+CD25+FOXP3+ regulatory T cells (Treg) are highly activated in tumors and promote disease progression. Specific, universal targeting of these effector Treg cells is limited by the lack of a conserved signature across human cancers and information on their origin. Here we combine analysis of single-cell RNA-sequencin...

J. Swatler, S. Puccio, Emanuele Voulaz et al. · 0 citations
Open access Sep 2026

HLA-II Expression Marks Activated and Clonally Expanded CD8+ T Cells and Improves Tumor-Reactivity Prediction Across Human Cancers

Tumor-infiltrating CD8+ T cells are transcriptionally heterogeneous, and robust features linking their clonal dynamics to experimentally defined tumor reactivity remain incompletely characterized. We integrated single-cell RNA sequencing (scRNA-seq) and paired T-cell receptor sequencing (scTCR-seq) data from 31 single-...

Xue Mi, Jing-Hua Zhu, Zhu Dai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.